



# AGENDA

## POETIC Fall Meeting

September 27<sup>th</sup> – September 29<sup>th</sup>, 2023  
Huntsman Cancer Institute/University of Utah  
Salt Lake City, Utah

### WEDNESDAY, SEPTEMBER 27

**EVENING SESSION**  
4:00 PM MT (6:00 PM EST)

Huntsman Cancer Institute Research South, 4<sup>th</sup> Floor  
Conference Room 4C

3:30 PM

**Shuttle bus service: University Marriott Hotel to HCI**

3:45 – 4:00 PM

**REGISTRATION**

4:00 – 5:00 PM MT (6:00  
– 7:00 EST)

**PI MEETING (Closed Session)**

5:00 – 7:00 PM MT (7:00  
– 9:00 EST)

**BOARD OF DIRECTORS MEETING (Closed Session)**

7:15 – 8:15 PM MT

**DINNER – HUNTSMAN CANCER INSTITUTE**

Open to all attendees (Non-Board of Directors, Non-PIs please RSVP)

### THURSDAY, SEPTEMBER 28

**MORNING SESSION**  
8:00 AM – 1:15 PM MT

Huntsman Cancer Institute Research South, 1<sup>st</sup> Floor  
J Willard and Alice S Marriott Foundation Auditorium

7:45 AM

**Shuttle bus service: University Marriott Hotel to HCI**

8:00 – 8:30 AM

**REGISTRATION/BREAKFAST**

8:30 – 9:00 AM

**GREETINGS/INTRODUCTIONS/WELCOME ADDRESS**

*Neli Ulrich, MS, PhD, Chief Scientific Officer and Executive Director, Comprehensive Cancer Center at Huntsman Cancer Institute, Jon M. and Karen Huntsman Presidential Professor in Cancer Research, Dept. of Population Health Sciences, University of Utah*

*Luke Maese, DO and Priya Chan, MD, University of Utah, Huntsman Cancer Institute, Primary Children's Hospital*

*Norman Lacayo, MD, Director, POETIC; Lucile Packard, Stanford University*

---

## KEYNOTE LECTURE

---

9:00 – 9:40 AM  
***Sharpening Our Tools: Use of Biomarkers and Targeted Dosing/PK to Improve Outcomes in Cell Therapy and HCT***  
*Michael Pulsipher, MD, Division Chief, Pediatric Hematology at Intermountain Primary Children's Hospital and Oncology, Director Children's and Adolescent Cancer Initiative at Huntsman Cancer Institute*

---

**9:40 – 12:15 pM**  
**POETIC TRIALS IN PROGRESS, DEVELOPMENT, AND OPPORTUNITIES FOR FUTURE COLLABORATION**

---

9:40 – 10:05 AM  
***Total Therapy for Infants with Acute Lymphoblastic Leukemia, TINI 2 Study***  
*Tanja Gruber, MD, Lucile Packard, Stanford University*

---

10:05 – 10:25 AM  
***Talazoparib in Combination With Conventional Chemotherapy for AML, PARPAML trial (POE22-01)***  
*Jennifer Kamens, MD, Lucile Packard, Stanford University*

---

10:25 – 10:50 AM  
***Vectosertib for Osteosarcoma***  
*Alex Huang, MD, PhD, Rainbow Babies and Children's Hospital, Case Western Reserve University*

---

10:50 – 11:00 AM  
**BREAK**

---

11:00 – 11:20 AM  
***iMATRIX IDASA Update (VIRTUAL)***  
*Ron Bernardi, MD, PhD, Genentech*

---

11:20 – 11:45 AM  
***Pediatric Real World CarT Consortium and the FORESIGHT Study***  
*Liora Schultz, MD, Lucile Packard, Stanford University*

---

11:45 – 12:15 PM  
***Pediatric oncology drug development: Oncoheroes' approach***  
*Cesare Spadoni, PhD, Oncoheros*

---

**12:15 – 1:15 PM**  
**LUNCH**

**12:45 – 1:15 PM**  
**OPTIONAL TOUR OF HUNTSMAN CANCER INSTITUTE**

**AFTERNOON SESSION**  
**1:15 – 5:00 PM**  
**Huntsman Cancer Institute Research South, 1<sup>st</sup> Floor**  
**J Willard and Alice S Marriott Foundation Auditorium**

---

## KEYNOTE LECTURE

---

1:15 – 2:00 PM  
***Developing therapeutics for a pediatric, adolescent, young adult cancer: Lessons from Fibrolamellar carcinoma.***  
*Sandford Simon, PhD, GÜNTER BLOBEL PROFESSOR, The Rockefeller University*

---

**2:00 – 5:00 PM**  
**DEVELOPMENTAL THERAPEUTICS, FOCUS ON SOLID TUMORS**

---

2:00 – 2:20 PM  
***Targeted engagement of the osteosarcoma immune microenvironment***  
*Matt Dietz, DO, University of Utah, Huntsman Cancer Institute, Primary Children's Hospital*

---

2:20 – 2:40 PM  
***Osteosarcoma preclinical models***  
*Ram Rao, MD, PhD Lucile Packard, Stanford University*

---

2:40 – 3:00 PM <b>(VIRTUAL)</b>	<b>Preclinical efforts for treatment of childhood cancer</b> <i>Raushan Kurmasheva, PhD, UT Health San Antonio, Greehey Children's Cancer Research Institute</i>
3:00 – 3:15 PM	<b>BREAK</b>
3:15 – 3:40 PM	<b>Novomedix Developmental Therapeutic Pipeline</b> <i>Cathy Swindlehurst, PhD, Novomedix</i>
3:40 – 4:00PM <b>(VIRTUAL)</b>	<b>Vincerix</b> <i>Amy Johnson, PhD, Vincerix</i>
4:00 – 5:00PM <b>(Open discussion)</b>	<b>POETIC Solid Tumor Working Group</b> <i>Anne-Marie Langevin, MD, UT Health San Antonio</i>
<b>5:00 PM</b>	<b>MEETING ADJOURN</b> <b>Shuttle bus service: HCI to University Marriott Hotel</b>
<b>6:30 – 8:30 PM</b>	<b>DINNER – <a href="#">SALT AND OLIVE</a> (270 S 300 E, SLC, UT 84111)</b>
<b>6:15 PM</b>	<b>Shuttle bus service: University Marriott Hotel to Salt and Olive</b>
<b>8:30 PM</b>	<b>Shuttle bus service: Salt and Olive to University Marriott Hotel</b>

## FRIDAY, SEPTEMBER 29

<b>MORNING SESSION</b> <b>8:00 AM – 12:45 PM</b>	<b>Huntsman Cancer Institute Research South, 1<sup>st</sup> Floor</b> <b>J Willard and Alice S Marriott Foundation Auditorium</b>
7:30 AM	<b>Shuttle bus service: University Marriott Hotel to HCI</b>
7:45 – 8:15 AM	<b>BREAKFAST</b>
<b>8:15 – 9:00 AM</b>	<b>ADVOCACY AND OUTREACH</b>
8:15 – 8:40 AM	<b>'They Call Me Brave'</b> <i>Shane Nebbia, Children's book author and advocate</i>
8:40 – 9:00 AM	<b>International Children's Cancer Research Centre in Ghana</b> <i>Tanya Trippett, MD, Co-Founder and Director Emeritus, POETIC; Memorial Sloan Kettering Cancer Center</i>
<b>9:00 – 11:35 AM</b>	<b>PRECLINICAL EFFORTS, DEVELOPMENTAL THERAPEUTICS, AND A FOCUS ON CNS TUMORS</b>
9:00 – 9:25 AM	<b>Development of an Active Chimeric IL13Ra2 ADC for Diffuse Intrinsic Pontine Glioma</b> <i>Charles Keller, MD, Children's Cancer Therapy Development Institute</i>
9:25 – 9:45 AM	<b>Ongoing Preclinical studies and Drug Development</b> <i>Aru Narendran, MD, PhD, Alberta Children's Hospital, University of Calgary</i>
9:45 – 10:05 AM	<b>A Phase 1 Study of Magrolimab in Children and Adults with Recurrent or Progressive Malignant Brain Tumors</b> <i>Nicholas Whipple, MD, MPH, University of Utah, Huntsman Cancer Institute, Primary Children's Hospital</i>

10:05 – 10:30 AM <b>(VIRTUAL)</b>	<b>Tumor Treating Fields (TTFields) - beyond GBM</b> <i>Moshe Giladi, PhD, Novocure</i>
10:30 – 10:50 AM <b>(VIRTUAL)</b>	<b>Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer</b> <i>Ted Johnson, MD, PhD, Children's Hospital of Georgia, Georgia Cancer Center, Augusta University</i>
10:50 – 11:00 AM	<b>BREAK</b>
11:00 – 11:35 AM <b>(Group discussion)</b>	<b>POETIC CNS Tumor Working Group</b> <i>Amy Smith, MD, Orlando Health - Arnold Palmer Children's Hospital</i> <i>Kevin Bielamowicz, MD, Arkansas Children's Hospital</i>
<b>11:35 AM – 12:30 PM</b>	<b>HEMATOPOETIC MALIGNANCIES</b>
11:35 AM – 12:00 PM <b>(VIRTUAL)</b>	<b>CK2 inhibitor for treatment of AYAs with Relapsed/Refractory Leukemia</b> <i>Chandrika Gowda, MD, Penn State University</i>
12:00 – 12:30 PM <b>(Group discussion)</b>	<b>POETIC Leukemia/Lymphoma Working Group</b> <i>Luke Maese, DO, University of Utah, Huntsman Cancer Institute, Primary Children's Hospital</i>
<b>12:30 – 12:45 PM</b>	<b>MEETING RECAP</b> <i>Luke Maese, DO, and Priya Chan, MD, University of Utah, Huntsman Cancer Institute, Primary Children's Hospital</i> <i>Norman Lacayo, MD, Director, POETIC; Lucile Packard, Stanford University</i>
<b>12:45 PM</b>	<b>LUNCH</b>
	<b>MEETING ADJOURN</b>

